Bank of America Upgrades Fresenius Medical Care (NYSE:FMS) to Neutral

Fresenius Medical Care (NYSE:FMS) was upgraded by equities research analysts at Bank of America from an “underperform” rating to a “neutral” rating in a report issued on Monday,Finviz reports.

A number of other brokerages also recently issued reports on FMS. Truist Financial raised their price target on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Berenberg Bank initiated coverage on Fresenius Medical Care in a research note on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price for the company. Finally, StockNews.com initiated coverage on Fresenius Medical Care in a research note on Thursday. They issued a “strong-buy” rating on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $24.30.

Fresenius Medical Care Price Performance

FMS stock opened at $22.52 on Monday. Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $22.76. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The firm has a market capitalization of $13.22 billion, a PE ratio of 18.61, a price-to-earnings-growth ratio of 1.01 and a beta of 0.91. The business has a 50 day simple moving average of $20.97 and a 200-day simple moving average of $20.30.

Institutional Trading of Fresenius Medical Care

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wulff Hansen & CO. grew its position in Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after purchasing an additional 325,439 shares during the last quarter. Moran Wealth Management LLC grew its holdings in shares of Fresenius Medical Care by 47.0% during the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock worth $4,971,000 after buying an additional 74,621 shares during the last quarter. Quantinno Capital Management LP grew its holdings in shares of Fresenius Medical Care by 78.9% during the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after buying an additional 48,554 shares during the last quarter. Crossmark Global Holdings Inc. increased its position in Fresenius Medical Care by 60.4% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock valued at $1,340,000 after acquiring an additional 23,692 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Fresenius Medical Care during the 3rd quarter valued at approximately $420,000. Institutional investors and hedge funds own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.